Physician

Jonathan David Greifenkamp, MD

According to 2025 Medicare claims, Jonathan Greifenkamp, MD (NPI: 1235333808) practices cardiology in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is REGIONAL CLINICS OF LONGVIEW (NPI: 1407047863; TIN: 20-4791426) and primary practice location at 75605-2412. Greifenkamp is affiliated with the CHSPSC ACO 8, LLC (ACO ID: A3715), participating under the MSSP model.

Greifenkamp's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,459 traditional Medicare patients, billed 8,798 HCPCS/CPT codes, and received $578,767 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 4,953 prescription claims across 809 beneficiaries totaling $833,491 in drug costs, led by Eliquis (Apixaban). 2021 DME data shows 17 claims. Open Payments data shows 156 records totaling $2,607. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $265,281 to $833,491. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $48,815 and ending at $42,577.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,233	7,521	$620,012
2016	2,454	7,869	$487,773
2017	1,909	7,416	$524,508
2018	1,379	5,292	$472,072
2019	1,354	6,289	$658,670
2020	1,382	5,966	$560,502
2021	1,280	6,101	$585,668
2022	1,206	5,565	$497,517
2023	1,338	5,724	$517,781
2024	1,459	8,798	$578,767

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	448	4,383	$265,281
2016	462	4,474	$307,665
2017	521	4,890	$360,139
2018	554	4,720	$375,132
2019	566	4,791	$434,974
2020	592	4,818	$446,665
2021	674	4,834	$565,667
2022	673	5,089	$680,435
2023	793	5,351	$901,074
2024	809	4,953	$833,491

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	21	$42,502
2016	N/R	11	$1,125
2017	N/R	17	$33,924
2018	N/R	32	$63,742
2019	12	38	$60,089
2020	N/R	N/R	N/R
2021	N/R	17	$38,533
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	405	426	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	380	440	$84
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	300	322	$55
93015	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician	252	253	$48
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	287	303	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	342	16,785	$320,517
Repatha Sureclick	Evolocumab	128	6,412	$121,866
Xarelto	Rivaroxaban	110	5,700	$104,036
Jardiance	Empagliflozin	109	3,810	$74,778
Entresto	Sacubitril/Valsartan	47	2,857	$60,845

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	156	$2,607	Biosense Webster, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jonathan David Greifenkamp, MD?

Tedicare shows public-source Medicare data for Jonathan David Greifenkamp, MD (NPI 1235333808), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jonathan David Greifenkamp, MD have ACO affiliation data?

Jonathan David Greifenkamp, MD is shown with ACO affiliation data for CHSPSC ACO 8, LLC (MSSP, ACO ID A3715).

What billing organization is linked to Jonathan David Greifenkamp, MD?

Jonathan David Greifenkamp, MD is linked to REGIONAL CLINICS OF LONGVIEW (billing NPI 1407047863) in the available physician profile data.

Does Jonathan David Greifenkamp, MD have Open Payments data?

Jonathan David Greifenkamp, MD has 156 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.